The company releases a 6k announcing positive results of the in-life phase of its toxicology study. Shares are at $3.09 on more than 36,000 trades.
https://neurosense.investorroom.com/sec-filings
The company releases a 6k announcing positive results of the in-life phase of its toxicology study. Shares are at $3.09 on more than 36,000 trades.
https://neurosense.investorroom.com/sec-filings
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
© 2022-2023 24/7MarketNews – The Experts in Investor and Public Relations